Fiche publication
Date publication
avril 2010
Résumé
Lipoprotein kinetic abnormalities in patients with Type 2 diabetes, are the basis of diabetic dyslipidemia, which is likely to play an important role in the development of atherogenesis. In Type 2 diabetes, all lipoproteins (VLDL, IDL, LDL and HDL) demonstrate significant kinetic abnormalities. Hypertriglyceridemia is due mainly to increased production of VLDL (mostly large VLDL1 particles, potentially atherogenic) and, to a lesser extent, to reduced catabolism of VLDL and IDL. Low HDL-C is the result of increased catabolism of HDL. Although plasma LDL-C level is usually normal in patients with Type 2 diabetes, LDL turnover is significantly reduced and, as a consequence, LDL plasma residence time is increased, which is potentially harmful. The pathophysiology of lipid kinetic abnormalities in Type 2 diabetes has not yet been completely explained. However, insulin resistance and the 'relative' insulin deficiency observed in patients with Type 2 diabetes, are likely to play a key role in lipid kinetic abnormalities since insulin has an important function in the regulation of lipid metabolism. In addition, adiponectin, which is present in low levels in patients with insulin resistance and Type 2 diabetes, could also be directly involved in some lipoprotein kinetic abnormalities.
Référence
Clin Lipidol. 2010 Apr;5(2):277-89.
